Welcome to our dedicated page for Opsens news (Ticker: OPSSF), a resource for investors and traders seeking the latest updates and insights on Opsens stock.
Opsens Inc. (OPSSF) is a medical device company focused on cardiology solutions. Recently, they have entered into an acquisition agreement with Haemonetics Corporation for CAD $2.90 per share. Opsens offers optical technology products for use in interventional cardiology, including SavvyWire® and OptoWire®. With a strong emphasis on patient outcomes and innovative solutions, Opsens aims to revolutionize the field of cardiology.
Rhea-AI Summary
Haemonetics to acquire OpSens for $253 million in cash, expanding its hospital portfolio with innovative fiber optic sensor technology for interventional cardiology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the market cap of Opsens (OPSSF)?
The market cap of Opsens (OPSSF) is approximately 247.4M.
What is Opsens Inc. known for?
Opsens Inc. is known for its optical technology products used primarily in interventional cardiology, such as SavvyWire® and OptoWire®.
What recent acquisition has Opsens Inc. been involved in?
Opsens Inc. has recently entered into an acquisition agreement with Haemonetics Corporation for CAD $2.90 per share.
What are the core products of Opsens Inc.?
Opsens Inc.'s core products include the SavvyWire®, a sensor-guided 3-in-1 guidewire for TAVR procedures, and the OptoWire®, a pressure guidewire for diagnosing and treating patients with coronary artery disease.
How does Opsens Inc. contribute to the field of cardiology?
Opsens Inc. aims to improve clinical outcomes by providing accurate and consistent measurements with their optical technology products, ultimately benefiting both clinicians and patients.
What is the goal of Opsens Inc. in the medical device industry?
Opsens Inc. strives to maximize patient benefits and value for customers by leveraging their proprietary optical sensor technology and global commercial infrastructure.
Opsens Inc.